StockWatch
·
TUBE INVESTMENTS OF INDIA LTD · QQ2 FY-2027 · THE CALL

Strong growth masked by cost pressure, TICMPL execution risk

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsTIINDIATube Investments of India Ltd11 Nov 2026 · 6 min read
Verdict

Hold

confidence 6/10

Credibility

Grade B

Prior guidance (double-digit growth, margin recovery) intact; FY27 EV breakeven targets on track but volume/cost misses narrowing margin of safety.

Short-term outlook

Cautiously Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

TI delivered strong consolidated revenue growth (33% YoY) and PAT growth (39%), with core segments healthy. However, near-term margin recovery is uncertain—commodity and FX headwinds are acute, and TICMPL (high-capex EV venture) volumes are below management's own comfort level, with profitability still 2-4 quarters away. Stock down 50% from Oct 2024 suggests market skepticism on capital efficiency.

₹7330.3 Cr

Revenue · +32.7% YoY

₹420.6 Cr

Reported PAT · +39.2% YoY

Compressing

Margins · vs guidance: Corroborated

Did the claims hold up?

Management's claims vs. the numbers

Double-digit growth trajectory at consolidated level

MET

32.7% YoY revenue growth, 39.2% PAT growth

Medical business growing 20% YoY with profitability

MET

Confirmed on call; exact Q2 contribution not itemized separately

Cost headwinds will be recovered in next 1-2 quarters

OVERSTATED

Q2 margins compressed (10% OPM vs prior guidance); recovery timing unverified

TICMPL volumes scaling across four businesses

MISS

Q2: Truck 311, 3W 2,242, SCV 483, Tractor 50 units; analyst noted 'not happy, should be higher'

TICMPL HCV will be EBITDA breakeven Q4 FY27

Unverified

Breakeven target stated; not yet achieved; costs 75% above run-rate

Earnings quality

What changed since the last call

Deltas vs. the prior call

Cost pressure intensity

Downgrade

Commodity and FX headwinds more acute than prior call implied; recovery pushed to 1-2 quarters vs immediate (i.e., delay in margin normalization).

TICMPL capital requirement

Neutral

Rs 250 Cr Q3 investment confirmed; total Rs 600-700 Cr annual group capex plan reaffirmed (no change).

EV breakeven timeline

Neutral

HCV Q4 FY27, two others Q4 FY28 reaffirmed; no movement vs prior call.

The Q&A

Analysts pressed hard on TICMPL volumes (Vipulkumar: 'should be higher'), profitability lag (Salil Desai: costs 75% above run-rate), and capital allocation (Gnanasundaram: why accumulate cash?). Management held confident but hedged on price increases ('market may not be ready') and blamed external factors (commodity, FX). Credibility strained by acknowledgment of miss.

The exchanges that mattered

TICMPL volume scaling — Vipulkumar Shah, Sumangal Investments

Answered

I am not happy with any of the four numbers. All four should be higher. Competition intensifying but we have 25-26% market share in two, targeting leadership.

TICMPL profitability gap — Salil Desai, Marcellus Investment Managers

Partial

Commodity costs, cell prices, rupee weakness drove BOM cost increase. We will take price hikes, reduce costs via BOM optimization, and improve deal realization. Timeline uncertain.

Operating margin stagnation — Gopalakrishnan S, Uthrasuuli Investment

Dodged

T1, T2, T3 strategy: core business focus, new initiatives, selective acquisitions. Will achieve double-digit growth and higher margins. TICMPL is a major opportunity. Profitability a matter of time and confidence.

TICMPL breakeven credibility — Rushabh Shah, RBSA Investment Managers

Partial

Four businesses at different maturity stages. Scale, BOM cost focus, after-sales support, and new use cases will drive profitability. Two-three tailwinds under way. Timeframe firm but execution-dependent.

Medical profitability — Anupam Gupta, HDFC MF

Partial

Will take time to stabilize. Our perspective is higher double-digit teen numbers. Once investments settle and team in place (by Q3), profitability will improve significantly.

Core business capex and cash flow — Gnanasundaram S, Avendus Park

Answered

TICMPL, medical, CDMO are major investments internally funded. Will deploy cash opportunistically into new ventures if right opportunity appears. Not holding excess; working on capital allocation principles.

International business headroom — Gnanasundaram S, Avendus Park

Answered

Geopolitical issues prevented growth. Now stabilized at 15% from TI level. Customer contracts running well; no walkouts. Will revisit growth if geopolitical stabilizes.

Guidance

Forward guidance and management's confidence

FY27 double-digit growth trajectory at consolidated level

High

Q2 delivered 33% YoY; guidance reaffirmed with T1, T2, T3 strategy focus on core and new ventures.

Higher double-digit EBIT margin improvement, cost recovery in 1-2 quarters

Medium

Commodity and FX headwinds to reverse; pricing lag of 1-2 quarters acknowledged; recovery unproven.

Medical business to achieve higher double-digit teen profitability margins

Medium

Post-Q3 when team in place; investment phase ongoing; amortization drag Rs 4 Cr/quarter.

Rs 350 Cr (TI) + Rs 100 Cr (Shanthi); total group Rs 600-700 Cr FY27

High

TICMPL dominant consumer (Rs 250 Cr Q3 planned); medical and CDMO incremental.

Risks the call surfaced

Ranked by how much they should concern a holder

TICMPL execution & profitability

High

Four EV businesses underperforming; HCV 311 units Q2, 3W 2,242 units, SCV 483 units. Analyst feedback: 'not happy with any numbers.' Breakeven Q4 FY27 depends on cost absorption and price increases.

Commodity and FX headwinds

High

Cell prices, commodity surge, and rupee weakness drove BOM cost increase across all businesses. Recovery timeline 1-2 quarters; market pricing power uncertain. Engineering and metal divisions margin compression evident.

Capital allocation efficiency

High

Rs 600-700 Cr annual group capex with TICMPL as dominant sink. External PE partner (Rs 2,250 Cr original investment) has NOT invested further despite planned Rs 250 Cr each in Q3 and beyond. TI funding alone; leverage/cash burn risk.

Customer concentration in emerging segments

Medium

Mining segment is 40% of truck revenue base. Electrification adoption depends on mining sector growth, charging infrastructure, and battery economics. Fixed-route operators concentrated in select cities (Bengaluru, Delhi, Ahmedabad).

New venture profitability timeline

Medium

Medical business growing 20% but profitability deferred; CDMO regulatory approval still ~1 year away. Amortization drag Rs 4 Cr/quarter; sustainable margins (double-digit teen) post-Q3, unproven.

Management

Score 6/10. Transparent on segment numbers and cost pressures; hedged on price increases and breakeven credibility. No forward-looking revenue/margin targets quantified. Defensive when pressed on TICMPL volumes. Prior guidance on double-digit growth (met: 33% delivered), EV breakeven timeline (on track Q4 FY27), and medical 20% growth (confirmed) tracking. Margin recovery timeline extended 1-2 quarters due to cost pressures; not a miss but a delay.

What to watch next
  • 1 · Q3 & Q4 FY27

    Cost pass-through to customers; commodity price softening expected

  • 2 · Q4 FY27

    TICMPL HCV EBITDA breakeven target

  • 3 · Q1 FY28

    TICMPL SCV and 3-wheeler breakeven; medical profitability ramp

Stock down 50% from Oct 2024 suggests market skepticism on capital efficiency.

Informational and educational content only. Not investment advice.